Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BMRNthis companyBioMarin Pharmaceutical Inc.	$56.07	32.65×	1.87×	3.54×	18.73×	-87.5%	77.1%	16.6%	10.8%	5.7%	5.6%	6.4%	0.11×	-1.17×	48.95×	5.21×	0.0%	3	0.33	3	B
ALNYAlnylam Pharmaceuticals, Inc.	$156.13	166.38×	66.01×	14.03×	81.9×	-1017.9%	81.8%	13.5%	8.4%	39.8%	13.7%	0.9%	1.62×	-0.6×	1.99×	2.76×	0.0%	5	3.79	4	A-
BBIOBridgeBio Pharma, Inc.	$75.34	-20.18×	-7.27×	30.05×	-25.49×	-271.4%	94.4%	-113.3%	-145.3%	35.1%	-108.5%	-3.0%	-1.31×	-3.19×	-10.72×	2.62×	0.0%	2	-0.07	2	C
INSMInsmed Incorporated	$114.81	-27.15×	50.31×	61.31×	-31.96×	-253.3%	79.4%	-194.0%	-210.5%	-172.8%	-64.8%	-2.6%	1.04×	-0.22×	-14.04×	3.83×	0.0%	4	6.45	1	D+
IONSIonis Pharmaceuticals, Inc.	$28.90	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
PTCTPTC Therapeutics, Inc.	$64.60	8.85×	-29.43×	3.49×	8.75×	-1377.4%	95.9%	49.5%	39.4%	-332.5%	33.4%	6.8%	-13.19×	1.94×	5.63×	2.35×	0.0%	4	0.75	2	C
Peer median	—	-20.18×	25.88×	14.03×	-25.49×	-292.2%	94.4%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	1.04×	-0.6×	-4.22×	2.76×	0.0%	4	0.89	2	—